Abstract: Invented is a novel pharmaceutical composition containing Paroxetine.

Abstract: A capsule dosage form containing solid form of terazosin in a solid carrier is disclosed. The capsule dosage form is stable under accelerated stability conditions and therapeutically equivalent to known liquid-filled terazosin capsules.

Abstract: Stable oil-in-water emulsions are prepared by mixing oil, water and an insoluble protein at high shear. By varying the amount of insoluble protein the emulsions may be made liquid, semisolid or solid. The preferred insoluble proteins are insoluble fibrous proteins such as collagen. The emulsions may be medicated with hydrophilic or hydrophobic pharmacologically active agents and are useful as or in wound dressings or ointments.

Abstract: A composition, comprising (a) microcrystalline cellulose; and (b) a compressibility augmenting agent which (i) physically restricts the proximity of the interface between adjacent cellulose surfaces; or (ii) inhibits interactions between adjacent cellulose surfaces; or (iii) accomplishes both (i) and (ii) above, is disclosed. The composition is in the form of agglomerated particles of microcrystalline cellulose and the compressibility augmenting agent in intimate association with each other.

Abstract: The invention provides an agglomerate composition composed of units of aggregated fine particles and methods for its manufacture and use. The agglomerate composition units are composed of fine particles having a mean particle size in the range of 1 .mu.m to 5 .mu.m, and usually includes a medicament powder. The agglomerate units have a mean size in the range from 200 .mu.m to 500 .mu.m and have a friability index in the range from about 10 to 60.

Abstract: Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: Methods for transporting a biologically active agent across a cellular membrane or a lipid bilayer. A first method includes the steps of:(a) providing a biologically active agent which can exist in a native conformational state, a denatured conformational state, and an intermediate conformational state which is reversible to the native state and which is conformationally between the native and denatured states;(b) exposing the biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex; and(c) exposing the membrane or bilayer to the supramolecular complex, to transport the biologically active agent across the membrane or bilayer. The perturbant has a molecular weight between about 150 and about 600 daltons, and contains at least one hydrophilic moiety and at least one hydrophobic moiety.

Abstract: A controlled release antihyperglycemic tablet that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane coating the core and at least one passageway in the membrane.

Abstract: The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical compostion which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower intestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which sometimes accompanies the oral administration of risedronate active ingredients.

Abstract: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.

Abstract: The invention is directed to a pharmaceutical composition which is a combination of the ACE inhibitor ramipril and a calcium antagonist of one of the dihydropyridine type compounds felodipine, nitrendipine, nifedipine and lacidipine. The pharmaceutical composition is for use in the therapy and treatment of hypertension.

Abstract: An effervescent granular preparation for keeping cut flower freshness includes an azole-substituted cyclopentanol derivative represented by formula (I) (set forth below) and 2-bromo-2-nitro-1, 3-propanediol as effective components and to a process for producing the same. The effervescent granular preparation is produced by granulation of a mixture containing at least one of glucose, D-mannitol and sucrose as an excipient by incorporating an organic acid such as citric acid or malic acid and a hydrogen carbonate such as sodium hydrogen carbonate. ##STR1## wherein A represents a nitrogen atom or a CH group, R.sup.1 and R.sup.2 represent each independently a hydrogen or a C.sub.1 -C.sub.3 alkyl group, and X represents a hydrogen atom or a halogen atom.

Abstract: Powder coated with a sparingly soluble ultraviolet light absorber which is prepared by a method in which the melted sparingly soluble ultraviolet light absorber and an inorganic or organic powder are mixed while heating and then gradually cooled to coat the surface of said powder with the sparingly soluble ultraviolet light absorber, or by a method in which the sparingly soluble ultraviolet light absorber is adsorbed to or made to coat the surface of the inorganic powder or organic powder using a mechanochemical method. The sparingly soluble ultraviolet light absorber can be blended in a high concentration in the system and blended homogeneously in the base agent. Also, stability over time is superior and the ultraviolet light protection effect is high.

Abstract: An apparatus for intraorgan administration of medicinal agents, such as, cells, growth factors, drugs and other agents under direct visualization, for example using an endoscope, by an apparatus and method which create needle channels within the target organ and deposits by injection, the medicinal agent in high concentrations at designated sites of the target organ. The device consists of a chamber having at least one retractable hollow bore needle; a reservoir for containing an injectable medicinal agent which is in communication with the needle and control means for extending and retracting the needle from and into the chamber and forcing the medicinal agent from the reservoir into the needle and injecting it into a target organ, said control means being suitable for effecting control through an endoscopic tube. Also disclosed are injection needles having side openings therein for enhanced administration of the medicinal agent to the target organ.

Abstract: The present invention relates to a novel pharmaceutical form, in the form of spheroids, containing one or more active principles, which the exception of tiagabine.The invention also covers the process for the preparation of such spheroids and multiparticulate pharmaceutical preparations, such as tablets, containing these spheroids.These pharmaceutical preparations are intended for the delivery of the spheroids they contain, and are characterized by the absence of an adverse effect on the release profile of the active principle(s) following a possible compression step.

Abstract: A cosmetic powder is provided which includes a crosslinked non-emulsifying siloxane elastomer, a powdered inorganic material and a skin treatment agent. Inclusion of the elastomer allows for the coupling of water as well as water soluble salts into the cosmetic powder.

Abstract: Methods for transporting a biologically active agent across a cellular membrane or a lipid bilayer. A first method includes the steps of:(a) providing a biologically active agent which can exist in a native conformational state, a denatured conformational state, and an intermediate conformational state which is reversible to the native state and which is conformationally between the native and denatured states;(b) exposing the biologically active agent to a complexing perturbant to reversibly transform the biologically active agent to the intermediate state and to form a transportable supramolecular complex; and(c) exposing the membrane or bilayer to the supramolecular complex, to transport the biologically active agent across the membrane or bilayer. The perturbant has a molecular weight between about 150 and about 600 daltons, and contains at least one hydrophilic moiety and at least one hydrophobic moiety.

Abstract: A peroral depot medicament with controlled active substance release is composed of a gelatine matrix that continuously dissolves in an aqueous medium above 37.degree. C., and a medicament distributed therein. The release of the medicament, that may be easily or scarcely soluble, lipophilic or hydrophilic, is variable in time and may be adjusted according to the medicament.

Abstract: A controlled-release dosage form of azithromycin having an improved side effect profile; a process for preparing the dosage form; and a method of treating a microbial infection, comprising administering azithromycin in such a controlled-release dosage form to a mammal, including a human patient, in need of such treatment.

Abstract: Control of inflammation is achieved by control of the level and/or activity of the enzyme heme-oxygenase (HO). A HO inducer is anti-inflammatory (FIG. 14) and used to treat inflammation, such as chronic inflammatory diseases. A HO inhibitor promotes inflammation and is used to treat immunosuppressed conditions. Alternative, or additional, control of heme-oxygenase activity is achieved by control of nitric oxide levels, elevated levels promoting inflammation.